PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells
Tobias Gutting, Veronika Hauber, Jens Pahl, Kay Klapproth, Wenyue Wu, Ioana Dobrota, F Herweck, Juliane Reichling, Laura Helm, Torsten Schroeder, Beifang Li, Philip Weidner, Tianzuo Zhan, Maximilian Eckardt, Johannes Betge, Sebastian Belle, Carsten Sticht, Timo Gaiser, Michael Boutros, Matthias Ebert, Adelheid Cerwenka, Elke Burgermeister
Abstract
gene. PPARγ-agonist reduced proliferation and viability of tumor cells in co-cultures with PD-L1 blocking Ab and lymphokine-activated killer cells (LAK) derived from the peripheral blood of CRC patients or healthy donors. Thus, metabolic modifiers improved the antitumoral response of immune checkpoint Ab, proposing novel therapeutic strategies for CRC.
Topics & Concepts
Colorectal cancerCancer researchMedicineCancerInternal medicineOncologyBiologyCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesCancer, Hypoxia, and Metabolism